SCMP - Sucampo Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD

Sucampo Pharmaceuticals, Inc.

805 King Farm Boulevard
Suite 550
Rockville, MD 20850
United States
301-961-3400
http://www.sucampo.com

SectorHealthcare
IndustryDrug Manufacturers - Other
Full Time Employees139

Key Executives

NameTitlePayExercisedAge
Mr. Peter S. GreenleafChairman & CEO1.28M2.02M47
Dr. Peter A. Kiener Ph.D.Chief Science Officer699.67kN/A65
Mr. Matthew Maxwell DonleyExec. VP of Global HR, Information Technology and Strategy668.63kN/A48
Mr. Peter P. Pfreundschuh CPAChief Financial OfficerN/AN/A48
Ms. Silvia Taylor MBASr. VP of Investor Relations and Corp. AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company’s marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.

Corporate Governance

Sucampo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.